ナカイ　ヨウスケ   NAKAI Yousuke   中井　陽介    所属   医学部 医学科（東京女子医科大学病院）    職種   教授・基幹分野長
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Predicting the risk of developing diabetes in steatotic liver disease using controlled attenuation parameter in a health checkup population
掲載誌名	正式名：Hepatology research 略　 称：Hepatol Res ISSNコード：13866346/13866346
掲載区分	国内
巻・号・頁	55(8),pp.1101-1110
著者・共著者	NAKATSUKA Takuma,YAMAJI Yutaka,TAKEISHI Ryosuke,OGASAWARA Takako,MIHARA Rena,KAWASHIMA Yoshiaki ,ONO Tetsuharu,YAMADA Tomoharu,MINAMI Tatsuya,SATO Masaya,HAYASHI Takeshi,MATSUSHITA Yuki,FUNATO Kazuyoshi,SATO Tatsuya,SAITO Tomotaka,KUDO Yotaro,KOGURE Hirofumi,NAKAGAWA Hayato,ASAOKA Yoshinari,TANAKA Yasuo,NAKAI Yosuke,IJICHI Hideaki,FUJISHIRO Mitsuhiro
発行年月	2025/08
概要	INTRODUCTION:Excessive hepatic steatosis is linked to systemic metabolic disorders. We investigated the association between hepatic steatosis quantified by controlled attenuation parameter (CAP) and the development of type 2 diabetes mellitus (T2DM) in a health checkup population.METHODS:The present retrospective cohort study included 1636 participants without T2DM who underwent CAP measurement and were followed up at annual health checkups. Cox proportional hazards regression was used to identify risk factors for T2DM development.RESULTS:During a mean follow-up of 3.2 years, 181 participants developed T2DM. The cumulative incidence rates of T2DM were significantly higher in participants with severe steatosis (CAP ≥ 280 dB/m) compared with those without (13.9% vs. 4.8% at 3 years, p < 0.001). Multivariate analysis identified CAP as an independent predictor of new-onset T2DM (adjusted hazard ratio [aHR], 1.04 per 10 dB/m increase; 95% confidence interval [CI], 1.01-1.08, p = 0.01), along with fasting plasma glucose (aHR, 2.13 per 10 mg/dL; 95% CI, 1.77-2.55, p < 0.001), HbA1c (aHR, 1.25 per 0.1% increase; 95% CI, 1.19-1.32, p < 0.001), and platelet count (aHR, 0.95 per 104/μL increase; 95% CI, 0.92-0.98, p = 0.001). A dose-response relationship was observed between CAP level and T2DM risk. In addition, suspected compensated advanced chronic liver disease (liver stiffness ≥10 kPa) and at-risk steatohepatitis (FibroScan-AST score ≥0.67) were associated with a higher incidence of T2DM (p < 0.001 for both).CONCLUSION:CAP quantification of hepatic steatosis effectively stratifies the risk of developing T2DM, facilitating timely intervention and prevention strategies.
DOI	10.1111/hepr.14216
PMID	40444737